Apr 15, 2020 / 02:40PM GMT
Alan Carr - Needham & Company, LLC, Research Division - Senior Analyst
Good morning, everyone. I'm Alan Carr, analyst at -- research analyst in Biotech at Needham & Company, and welcome to the second day of the 19th Annual Needham Healthcare Conference, and of course, our first virtual health care conference. I've got Lorence Kim, CFO of Moderna, with us here today.
How are you doing, Lorence?
Lorence H. Kim - Moderna, Inc. - CFO & Treasurer
Doing very well, Alan. Thank you for inviting us.
Questions and Answers:
Alan Carr - Needham & Company, LLC, Research Division - Senior AnalystAll right. So you had a long day yesterday. I figured we might start off with maybe a few high-level comments that you have about what was important and new yesterday from your vaccine programs. And we can sort of touch on COVID-19 a little bit after you go through the day yesterday.
Lorence H. Kim - Moderna, Inc. - CFO & Treasurer
Sure. Thanks, Alan. So yes,